ARNOLD & PORTER KAYE SCHOLER LLP for ADAPTIVE BIOTECHNOLOGIES
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to lab analysis and review of diagnostics and lab developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021 (H.R. 4128/S. 2209), the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S. 4348), and the Consolidated Appropriations Act, 2023 (P.L. No: 117-328).
| Lobbyist | Covered position, as disclosed |
|---|---|
| KRISTINE BLACKWOOD | — |
| CASEY BROUHARD | — |
| PETER ERIC DUYSHART | — |
| BOBBY MCMILLIN | — |
| PARI MODY | — |
| EUGENIA PIERSON | — |
Budget/Appropriations BUD
Federal funding support for cellular immunity research and utilization; including Fiscal Year 2022 (H.R. 4502) and Fiscal Year 2023 Labor, Health and Human Services, and Education, and Related Agencies appropriations issues (S. 4659; H.R. 8295), Fiscal Year 2023 Department of Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations issues (S. 4661; H.R. 8239; H.R. 8294), and the Consolidated Appropriations Act, 2023 (P.L. 117-328).
| Lobbyist | Covered position, as disclosed |
|---|---|
| KRISTINE BLACKWOOD | — |
| CASEY BROUHARD | — |
| PETER ERIC DUYSHART | — |
| BOBBY MCMILLIN | — |
| PARI MODY | — |
| EUGENIA PIERSON | — |
Medicare/Medicaid MMM
Issues related to the Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021 (S. 1873 & H.R. 1946).
| Lobbyist | Covered position, as disclosed |
|---|---|
| KRISTINE BLACKWOOD | — |
| CASEY BROUHARD | — |
| PETER ERIC DUYSHART | — |
| BOBBY MCMILLIN | — |
| PARI MODY | — |
| EUGENIA PIERSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.